35 citations
,
August 2004 in “Epilepsy & behavior” Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
50 citations
,
March 2011 in “European Journal of Endocrinology” Spironolactone improved blood vessel function and cholesterol levels in non-obese women with PCOS.
November 1982 in “Inpharma” Spironolactone reduces hair growth in women with unexplained excessive hairiness.
January 2004 in “Online Publication Service of Würzburg University (Würzburg University)” Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.
May 2024 in “Australasian journal of dermatology” Bicalutamide is more effective and safer than spironolactone for treating female hair loss.
18 citations
,
January 1990 in “Journal of The American Academy of Dermatology” Lower doses of dexamethasone can safely reduce high DHEAS levels in women with androgenic disorders.
February 2026 in “Clinical and Experimental Dermatology” Bicalutamide improved hair growth more than spironolactone in women with hair loss.
January 1993 in “Проблемы Эндокринологии” Spironolactone effectively reduces symptoms of hyperandrogenism but has some side effects.
January 1994 in “Journal of Dermatological Treatment” Spironolactone helped reduce excessive facial hair in a woman with porphyria cutanea tarda.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
39 citations
,
November 1978 in “Annals of internal medicine” Spironolactone may help reduce excessive hair growth in women with high male hormone levels.
November 2006 in “Reactions Weekly” A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.
1 citations
,
September 2020 in “Actas Dermo-Sifiliográficas”
September 2024 in “Advanced medical journal” Spironolactone is effective and safe for treating acne in women, especially those over 25 with hormonal imbalances.
1 citations
,
October 2011 in “Hospital Pharmacy”
3 citations
,
March 2024 in “International Journal of Women’s Dermatology” Spironolactone may help women with hidradenitis suppurativa.
11 citations
,
September 2022 in “Journal of the Endocrine Society” Young transgender, gender diverse, and nonbinary people on spironolactone have a low risk of high potassium, so frequent monitoring may not be needed.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
11 citations
,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
August 2021 in “Journal of The American Academy of Dermatology” Newer contraceptives with less androgenic progestins may reduce female hair loss.
23 citations
,
July 1989 in “Postgraduate medical journal” Spironolactone did not make hair thinner in women with excess hair growth.
60 citations
,
September 1979 in “Fertility and sterility” Spironolactone can reduce hair growth in women with hirsutism.
1 citations
,
January 2013 in “UNICA IRIS Institutional Research Information System (University of Cagliari)” Hormonal contraceptives may reduce social behavior and sexual motivation by lowering allopregnanolone levels.
4 citations
,
December 2021 in “Journal of The American Academy of Dermatology” Doctors are prescribing spironolactone more often to treat acne and skin conditions in teenagers, and it seems safe and well-tolerated.
July 2025 in “Dermatology Practical & Conceptual” Spironolactone is safe for treating hair loss in women without causing low blood pressure.
10 citations
,
May 2020 in “Journal of The American Academy of Dermatology” Taking spironolactone doesn't increase the chance of breast cancer coming back.
January 2026 in “Mendeley Data” January 2026 in “Mendeley Data” October 2022 in “British Journal of Dermatology”